A schizophrenia drug in Cerevel Therapeutics Inc.’s lineup understandably stole much of the thunder during coverage of Abbvie Inc.’s takeover late last year to the tune of $8.7 billion, but much further back in the pipeline awaits another potentially lucrative prospect: a kappa opioid receptor antagonist (KORA) for major depressive disorder (MDD).
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has described oxime-containing compounds acting as stimulator of interferon genes protein (STING; TMEM173) antagonists reported to be useful for the treatment of psoriasis, rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes, multiple sclerosis, inflammatory bowel disease, transplant rejection and neurodegeneration, among others.
Merck Sharp & Dohme LLC has identified compounds acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of atherosclerosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), neuroinflammation, inflammatory skin, inflammatory joint and autoimmune diseases, Alzheimer’s disease and Parkinson’s disease, among others.
Synaptogenix Inc. has entered into a new collaboration agreement with LSU Health New Orleans’ Neuroscience Center of Excellence for preclinical testing of the company’s polyunsaturated fatty acid (PUFA) analogues.
Cigarette smoke, the main cause of chronic obstructive lung disease, is considered a significant contributor of neuroinflammation, potentially leading to cognitive impairment and neurodegeneration. About 61% of individuals with chronic obstructive pulmonary disease have neurocognitive dysfunction.
Muscle fatigue associated with brain inflammation could be prevented by modulating certain cytokines. Researchers at Washington University in St. Louis (WUSTL) have studied inflammation in the CNS in infection models of Escherichia coli, SARS-CoV-2 and amyloid-β toxicity, unveiling its impact on motor function, the role of IL-6 in this process and how to mitigate it in chronic disease.
Researchers from the University of Southern California filed for protection of a thin film electrode array they developed to be implanted using endovascular methods for minimally invasive, high-resolution electrical recording and stimulation of the nervous system and other electrogenic tissue.
Myogenica Inc., a University of Minnesota startup company, has obtained IND approval from the FDA for Myopaxon, an induced pluripotent stem cell (iPSC)-derived muscle stem cell product to regenerate skeletal muscle. A planned study will evaluate intramuscular injections of Myopaxon in non-ambulatory adult patients with Duchenne muscular dystrophy.
Beyond its success in migraine and attention deficit hyperactivity disorder, Nu Eyne Co. Ltd. is advancing a portfolio of noninvasive, wearable trigeminal nerve stimulation devices across key three areas of neuromodulation, tissue regeneration and proliferation inhibition.
RSS
